DE60135315D1 - In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide - Google Patents

In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Info

Publication number
DE60135315D1
DE60135315D1 DE60135315T DE60135315T DE60135315D1 DE 60135315 D1 DE60135315 D1 DE 60135315D1 DE 60135315 T DE60135315 T DE 60135315T DE 60135315 T DE60135315 T DE 60135315T DE 60135315 D1 DE60135315 D1 DE 60135315D1
Authority
DE
Germany
Prior art keywords
differentially expressed
breast
polypeptides
bladder cancer
expressed gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135315T
Other languages
German (de)
English (en)
Inventor
Maurice Zauderer
Elizabeth E Evans
Melinda A Borrello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Application granted granted Critical
Publication of DE60135315D1 publication Critical patent/DE60135315D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60135315T 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide Expired - Lifetime DE60135315D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04
PCT/US2001/010855 WO2001074859A2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Publications (1)

Publication Number Publication Date
DE60135315D1 true DE60135315D1 (de) 2008-09-25

Family

ID=22717696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135315T Expired - Lifetime DE60135315D1 (de) 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Country Status (10)

Country Link
US (3) US7268207B2 (enExample)
EP (1) EP1272636B8 (enExample)
JP (1) JP2004502408A (enExample)
CN (2) CN1610743A (enExample)
AT (1) ATE404669T1 (enExample)
AU (2) AU2001253119B2 (enExample)
CA (1) CA2413211A1 (enExample)
DE (1) DE60135315D1 (enExample)
NZ (1) NZ522282A (enExample)
WO (1) WO2001074859A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413211A1 (en) * 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
EP1359937A4 (en) * 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2070949B1 (en) * 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005106044A1 (en) * 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
CN101505793A (zh) * 2006-06-22 2009-08-12 瓦西尼斯公司 用于治疗癌症的抗c35抗体
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
US8637026B2 (en) 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
PT2385980T (pt) 2009-01-08 2018-06-26 Albert Einstein College Medicine Inc Vacinas bacterianas com glicolípidos do tipo ceramida associados à parede celular e utilização dos mesmos
WO2010111792A1 (en) * 2009-04-01 2010-10-07 The University Of British Columbia Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
CN102639555B (zh) * 2009-09-24 2015-11-25 加利福尼亚大学董事会 膀胱癌特异性配体肽
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
MX2018007204A (es) * 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
IL273030B2 (en) * 2017-09-05 2024-03-01 Gritstone Bio Inc Neoantigen identification for t-cell therapy
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
WO2019199579A1 (en) 2018-04-09 2019-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing
KR102318018B1 (ko) 2019-07-05 2021-10-28 한국생산기술연구원 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드
IL292313A (en) * 2019-10-18 2022-06-01 Univ Leland Stanford Junior Clinical- and industrial-scale intact-tissue sequencing
CN115407064B (zh) * 2021-05-26 2025-09-23 复旦大学附属肿瘤医院 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (ja) * 1991-04-18 1993-04-02 Fujitsu Ltd 双曲線航法システムにおけるシステム監視処理方式
CA2141960A1 (en) 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
EP0703783B1 (en) 1993-03-05 2010-05-05 Epimmune Inc. Methods of making immunogenic hla-a2.1 binding peptides
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
JP2002507387A (ja) * 1997-12-24 2002-03-12 コリクサ コーポレイション 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
AU2342299A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
CA2413211A1 (en) * 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1274852A2 (en) 2000-04-12 2003-01-15 University Of Rochester Targeted vaccine delivery systems
DE60126130T2 (de) * 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP2070949B1 (en) * 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
WO2005099361A2 (en) 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Also Published As

Publication number Publication date
US20070081942A1 (en) 2007-04-12
US20020155447A1 (en) 2002-10-24
EP1272636B1 (en) 2008-08-13
US20090312263A1 (en) 2009-12-17
NZ522282A (en) 2005-03-24
WO2001074859A2 (en) 2001-10-11
JP2004502408A (ja) 2004-01-29
WO2001074859A3 (en) 2002-03-28
CA2413211A1 (en) 2001-10-11
AU5311901A (en) 2001-10-15
CN1610743A (zh) 2005-04-27
AU2001253119B2 (en) 2006-04-13
ATE404669T1 (de) 2008-08-15
CN101643732A (zh) 2010-02-10
EP1272636A2 (en) 2003-01-08
EP1272636B8 (en) 2008-10-08
US7268207B2 (en) 2007-09-11
US7910551B2 (en) 2011-03-22

Similar Documents

Publication Publication Date Title
DE60135315D1 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
WO2002016413A3 (en) Cripto tumour polypeptide
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
IL149046A (en) Composition comprising a polynucleotide encoding a 36p6d5 polypeptide for use in diagnosing cancer and diagnostic method related to 36p6d5
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
DE69839123D1 (de) Prostattumor polynukleotid- und antigenzusammensetzungen
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
EP2070949A3 (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
ATE350474T1 (de) Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
EP1536006A4 (en) CANCER-ANIMALS AND THEIR USE
TR200101702T2 (tr) Mammaglobin, göğse özgü salgılanan bir göğüs kanseri proteini.
DE69033810D1 (de) Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ATE108188T1 (de) Laminin bindende peptidfragmente.
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
WO2003024302A3 (en) Detection and treatment of cancers of breast
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
ATE330030T1 (de) Eine familie von genen mit transformationsmodulierender aktivität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition